Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis

Wong, Kristine; Higgins, Sara; Marqusee, Ellen; Nehs, Matthew A.; Angell, Trevor E.; Barletta, Justine A.

doi:10.1007/s12022-018-9561-4

Cited by 35 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When stratified in groups consisting of tall cell proportions (< 10%, 10–19%, 20–29%, and ≥ 30%), identification of at least 10% tall cell change was associated with worse outcome ( P = 0.002). In contrast, Wong et al [ 41 ] reported that only tumors with greater than 50% of tall cell component had a more aggressive behavior. Thus, the proportion of tall cell component that is clinically relevant is still a matter of debate.…”

Section: Aggressive Variants Of Ptcmentioning

confidence: 99%

“…It has been observed that its prevalence in TCV is between 80% and 100%. Wong et al [ 41 ] found that the higher frequency of BRAF mutations was found in cases with greater than 50% of tall cell component, and that these cases frequently have a pathogenic secondary mutation (usually in the TERT promoter gene). RET/PTC rearrangements have also been studied, with RET/PTC 3 described in 35.8% of TCV cases, compared with 17.2% in classic PTC [ 32 , 45 , 46 ].…”

Section: Aggressive Variants Of Ptcmentioning

confidence: 99%

See 1 more Smart Citation

Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

Introduction: Aggressive variants of papillary thyroid cancer (PTC) have been described with increasing frequency. These variants include diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, and hobnail variant. Methods: We have performed a review of the more aggressive variants of PTC with respect to main characteristics, histological and molecular features, and the consequences that the knowledge of these variants should have in the treatment of the patients. Results: At the present time, we do not know the prognostic value of these aggressive PTC variants. The extent of the surgical treatment and adjuvant therapy necessary should be decided on the basis of the extent of the tumor This article was written by members and invitees of the International Head and Neck Scientific Group (https:// www.IHNSG.com).

show abstract

Section: Aggressive Variants Of Ptcmentioning

confidence: 99%

Section: Aggressive Variants Of Ptcmentioning

confidence: 99%

Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Genetic ITH of PTCs was scarcely addressed so far, partly due to the relatively low number of oncogenes involved in the early stages [ 87 , 88 , 89 ] ( Table 3 ). BRAF mutations have been reported in 55% of the classical phenotype with a further significant increase in more aggressive and poorly differentiated PTCs [ 90 , 91 ], and in up to one third of cases of the columnar-cell variant [ 92 , 93 ]. In addition, BRAF mutations are frequently combined with TP53, TERTp, PIK3CA, catenin β-1 (CTNNB1), epidermal growth factor receptor (EGFR), v-akt murine thymoma viral oncogene homolog 1 (AKT1) and Notch homolog-1 (NOTCH1) mutations [ 83 , 94 , 95 , 96 ].…”

Section: Phenotypic and Molecular Heterogeneity In Ptc And Its Variantsmentioning

confidence: 99%

Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine

Ieni

Vita

Pizzimenti

et al. 2021

JPM

View full text Add to dashboard Cite

Differentiated thyroid tumors (DTTs) are characterized by significant molecular variability in both spatial and temporal intra-tumoral heterogeneity (ITH), that could influence the therapeutic management. ITH phenomenon appears to have a relevant role in tumor growth, aggressive behavior and drug resistance. Accordingly, characteristics and consequences of ITH in DTTs should be better analyzed and understood in order to guide clinical practice, improving survival. Consequently, in the present review, we investigated morphological and molecular ITH of DTTs in benign, borderline neoplasms and in malignant entities, summarizing the most significant data. Molecular testing in DTTs documents a high risk for recurrence of cancer associated with BRAFV600E, RET/PTC 1/3, ALK and NTRK fusions, while the intermediate risk may be related to BRAFK601E, H/K/N RAS and PAX8/PPARγ. In addition, it may be suggested that tumor genotype is associated with peculiar phenotype.

show abstract

“…Despite notable progress in the elucidation of genetic profiles of thyroid cancers, studies investigating the mutational profile of aggressive variant PTC are limited and unclear. The BRAF V600E mutation, which has emerged as a marker of aggressive behavior in thyroid cancer, was observed in 80–100% of TCV, 33% of CCV, and 25.3–57.1% of HV [ 9 , 10 , 11 , 12 , 13 ]. The RAS mutation, which may play an important role in follicular thyroid carcinogenesis, is more frequent and may be more relevant as a prognostic indicator in follicular pattern lesions (FV-PTC, follicular thyroid carcinoma (FTC), and PDTC) than in classical PTC [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas

Jin

Song

Ahn

et al. 2021

Cancers

View full text Add to dashboard Cite

Aggressive variants of papillary thyroid carcinoma (PTC) have been described with increasing frequency and are associated with unfavorable clinical outcomes. However, limited data exist on the comprehensive genetic profile of these variants. We performed targeted next-generation sequencing in 36 patients with aggressive variants of PTC and compared it to PTC from The Cancer Genome Atlas (TCGA) project and poorly differentiated thyroid cancers (PDTCs)/anaplastic thyroid cancers (ATCs) from the Memorial Sloan Kettering Cancer Center (MSKCC). BRAF mutation was the most prevalent (89%) in aggressive variants of PTC compared to that in other thyroid cancers. RAS mutation was identified in one patient (3%), which was less frequent than in others. TERT promoter mutation (17%) ranged between that of PTCs (9%) and PDTCs (40%). Tumor suppressor genes, ZFHX3, TP53, and CHEK2, were mutated in 14%, 3%, and 6% of aggressive variants of PTC, respectively. The mutation rate of TP53 (3%) was significantly higher than that of PTCs (0.7%) and lower than that of ATCs (73%). Mutations in three functional groups, histone methyl transferases, SWI/SNF chromatin remodeling complex, and the PI3K/AKT/mTOR pathway, were present in 11%, 14%, and 11% of samples, respectively. In conclusion, aggressive variants of PTC had higher BRAF and lower NRAS mutation prevalence than other thyroid cancers. The prevalence of mutations in the TERT promoter, TP53, and genes encoding three functional groups ranged between that of PTCs and PDTCs/ATCs.

show abstract

Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis

Cited by 35 publications

References 21 publications

Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review

Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review

Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine

Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas

Contact Info

Product

Resources

About